Kevzara® (sarilumab) – New indication
June 11, 2024 - Regeneron and Sanofi announced the FDA approval of Kevzara (sarilumab), for treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh 63 kg or greater
Download PDF
